Huadong Medicine Co., Ltd (SHE:000963)

Huadong Medicine Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	42,195	41,508	40,261	37,489	34,418	33,604
Other Revenue	420.43	397.3	362.43	226	145.56	78.83
Revenue	42,616	41,906	40,624	37,715	34,563	33,683
Revenue Growth (YoY)	3.43%	3.16%	7.71%	9.12%	2.61%	-4.97%
Cost of Revenue	28,224	28,006	27,468	25,686	23,969	22,555
Gross Profit	14,392	13,899	13,156	12,028	10,595	11,128
Selling, General & Admin	7,771	7,806	8,066	7,584	6,591	6,969
Research & Development	1,782	1,426	1,271	1,016	979.64	926.73
Other Operating Expenses	298.57	214.72	203.41	205.31	176.11	184.37
Operating Expenses	9,990	9,558	9,566	8,873	7,788	8,103
Operating Income	4,402	4,341	3,590	3,155	2,806	3,025
Interest Expense	-96.12	-96.95	-114.91	-120.04	-68.48	-68.64
Interest & Investment Income	96.47	104	94.05	103.35	80.4	60.99
Currency Exchange Gain (Loss)	6.03	-2.56	-1.04	-34.7	-2.27	-10.04
Other Non Operating Income (Expenses)	6.22	-27.16	-29.65	-27.16	-31.93	-16.68
EBT Excluding Unusual Items	4,414	4,318	3,538	3,076	2,784	2,990
Impairment of Goodwill	-	-	-	-	-2.92	-
Gain (Loss) on Sale of Investments	-148.61	-129.19	-233.47	-113.09	-96.31	-27.53
Gain (Loss) on Sale of Assets	-16.59	-5.46	4.32	8.26	-0.03	322.64
Asset Writedown	-26.49	-25.19	-5.14	-5.87	-5.09	-2.51
Other Unusual Items	223.44	143.19	161.87	65.6	147.89	170.41
Pretax Income	4,446	4,302	3,466	3,031	2,828	3,453
Income Tax Expense	836.83	807.33	619.59	498.5	488.91	543.67
Earnings From Continuing Operations	3,609	3,494	2,846	2,533	2,339	2,910
Minority Interest in Earnings	21.61	17.92	-7.54	-33.41	-37	-89.86
Net Income	3,631	3,512	2,839	2,499	2,302	2,820
Net Income to Common	3,631	3,512	2,839	2,499	2,302	2,820
Net Income Growth	17.09%	23.71%	13.59%	8.58%	-18.38%	0.24%
Shares Outstanding (Basic)	1,757	1,752	1,750	1,750	1,750	1,750
Shares Outstanding (Diluted)	1,758	1,753	1,752	1,750	1,750	1,750
Shares Change (YoY)	0.31%	0.08%	0.10%	0.00%	-0.00%	0.00%
EPS (Basic)	2.07	2.00	1.62	1.43	1.32	1.61
EPS (Diluted)	2.07	2.00	1.62	1.43	1.32	1.61
EPS Growth	16.73%	23.61%	13.47%	8.58%	-18.37%	0.24%
Free Cash Flow	2,072	2,021	2,323	1,189	2,351	1,938
Free Cash Flow Per Share	1.18	1.15	1.33	0.68	1.34	1.11
Dividend Per Share	0.930	0.930	0.580	0.290	0.290	0.230
Dividend Growth	-	60.35%	100.00%	-	26.09%	-17.86%
Gross Margin	33.77%	33.17%	32.38%	31.89%	30.65%	33.04%
Operating Margin	10.33%	10.36%	8.84%	8.37%	8.12%	8.98%
Profit Margin	8.52%	8.38%	6.99%	6.63%	6.66%	8.37%
Free Cash Flow Margin	4.86%	4.82%	5.72%	3.15%	6.80%	5.75%
EBITDA	5,234	5,091	4,318	3,778	3,316	3,456
EBITDA Margin	12.28%	12.15%	10.63%	10.02%	9.59%	10.26%
D&A For EBITDA	832.1	750.15	727.64	622.73	509.65	431
EBIT	4,402	4,341	3,590	3,155	2,806	3,025
EBIT Margin	10.33%	10.36%	8.84%	8.37%	8.12%	8.98%
Effective Tax Rate	18.82%	18.77%	17.88%	16.45%	17.29%	15.74%
Revenue as Reported	42,616	41,906	40,624	37,715	34,563	33,683

Source: S&P Global Market Intelligence. Standard template. Financial Sources.